Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease.
Authors:
Top Cited Papers
- 16 July 2026
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 395 (3) , 233-242
Abstract
Patients with multivessel coronary artery disease often receive 12 months of dual antiplatelet therapy (DAPT) after stenting to reduce the risk of ischemic events. Whether extending DAPT beyond 12 months in event-free patients with multivessel disease provides a benefit is uncertain. We conducted an open-label, randomized trial at 97 centers in China. Patients 18 to 75 years of age with multivessel coronary artery disease who had no major ischemic or bleeding events while receiving DAPT for 12 months after implantation of a drug-eluting stent were randomly assigned in a 1:1 ratio to receive an additional 12 months of DAPT (clopidogrel plus aspirin) or aspirin monotherapy. The primary efficacy end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The primary safety end point was clinically relevant or major bleeding (i.e., a bleeding event of Bleeding Academic Research Consortium [BARC] type ≥2; BARC types range from 0 to 5, with higher values indicating greater severity of bleeding). A total of 8250 patients were randomly assigned to receive extended DAPT (4125 patients) or aspirin monotherapy (4125 patients). The median follow-up was 34.3 months. A primary efficacy end-point event occurred in 222 patients in the DAPT group and in 266 patients in the aspirin-monotherapy group (36-month Kaplan-Meier cumulative incidence, 5.8% vs. 6.8%; hazard ratio, 0.82; 95% confidence interval [CI], 0.69 to 0.98; P = 0.03). Clinically relevant or major bleeding occurred in 51 patients in the DAPT group and in 57 patients in the aspirin-monotherapy group (36-month Kaplan-Meier cumulative incidence, 1.4% vs. 1.5%; hazard ratio, 0.89; 95% CI, 0.61 to 1.30; P = 0.54). Among patients with multivessel coronary artery disease who were in stable condition 12 months after implantation of a drug-eluting stent, extending DAPT with clopidogrel and aspirin for an additional 12 months led to a lower risk of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke than continuing aspirin alone, without an increased risk of bleeding. (Funded by the National Natural Science Foundation of China and others; DAPT-MVD ClinicalTrials.gov number, NCT04624854.).Keywords
Funding Information
- Chinese Society of Cardiology Clinical Research Special Fund Project (CSCF2020A02)
- The Tou-Yan Innovation Team Program of the Heilongjiang Province
- National Natural Science Foundation of China (62135002)
- National Natural Science Foundation of China (82525006)
- Lepu Medical Technology (Beijing) Co., Ltd
This publication has 30 references indexed in Scilit:
- Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trialThe Lancet, 2025
- Macrophage P2Y12 regulates iron transport and its inhibition protects against atherosclerosisJournal of Advanced Research, 2024
- Rationale and Design of Dual Antiplatelet Therapy in Patients with Coronary Multi‐Vessel Disease (DAPT‐MVD): A Multicenter, Randomized, Controlled TrialClinical Cardiology, 2024
- Identification of High-Risk Coronary Lesions by 3-Vessel Optical Coherence TomographyJACC, 2023
- Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trialThe Lancet, 2021
- Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history studyThe Lancet, 2021
- Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to ClopidogrelJACC: Cardiovascular Interventions, 2020
- Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary DiseaseJACC, 2018
- Association BetweenCYP2C19Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic AttackJAMA, 2016
- Blinding in randomised trials: hiding who got whatThe Lancet, 2002